Skip to main content
Fig. 3 | Respiratory Research

Fig. 3

From: Dose-response to inhaled glycopyrrolate delivered with a novel Co-Suspension™ Delivery Technology metered dose inhaler (MDI) in patients with moderate-to-severe COPD

Fig. 3

Primary endpoint: LSM change from baseline in FEV1 AUC0–12 on Day 14 (mITT population). Primary efficacy comparison for superiority to placebo: *p < 0.05; **p < 0.001; ***p < 0.0001. FEV 1 AUC 0–12 forced expiratory volume in 1 s, area under the curve from 0 to 12 h; GP glycopyrrolate; LSM least squares mean; MDI metered dose inhaler; mITT modified intent-to-treat

Back to article page